Karyopharm Therapeutics INC (KPTI) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Karyopharm Therapeutics Inc. has previously faced challenges maintaining compliance with Nasdaq’s minimum stock price requirement, receiving a deficiency notice when its share price fell below the $1.00 threshold. Although the company rectified this issue by sustaining the necessary bid price for the required duration, there is no certainty it will avoid future non-compliance. A potential delisting from the Nasdaq Global Select Market could significantly impair Karyopharm’s stock liquidity and ability to secure further capital, posing a substantial risk to its financial stability and shareholder value.
Overall, Wall Street has a Strong Buy consensus rating on KPTI stock based on 3 Buys and 1 Hold.
To learn more about Karyopharm Therapeutics INC’s risk factors, click here.
